ALIPAY+
11.11.2022 03:22:38 CET | Business Wire | Press release
Alipay+, a suite of cross-border payment and marketing solutions, has supported global online merchant partners to serve over 100 million e-wallet users as they flock to take up the offers and benefits since the global Double 11 event kicked off on November 1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221110006198/en/
Alipay+ is dedicated to bringing more exclusive offers and benefits from merchants around the world to hundreds of millions mobile-savvy consumers of its e-wallet partners. (Photo: Business Wire)
The consumers that participated in the event are mostly users of a dozen popular e-wallets from Southeast Asia, including GCash (The Philippines), TrueMoney (Thailand), Touch ’n Go eWallet (Malaysia), DANA (Indonesia) and Kakao Pay (South Korea). With Alipay+, these users can conveniently make cross-border payments with more than 1,000 global online merchants by using their local currency wallets on their respective platforms during the festival.
This year, e-wallet users could access coupons to exchange for free gifts and attractive deals offered by merchants listed on the Alipay+ Rewards section from their own payment apps. Consumers can also use direct payments at online checkout through e-wallets powered by Alipay+ solution, which ensures payments can be completed smoothly across the border, especially during the peak time of the festival.
From November 1 to 10, the number of online payment transactions via Alipay+ has recorded a significant growth of 40 percent compared to the previous year, while total e-wallet user payments through Alipay+ has experienced an increase of 30 percent. This is a testament to Alipay+’s increasing popularity and its capability to seamlessly execute cross-border payments and marketing.
In terms of transaction volume increase, the digital & entertainment sector saw the highest level of user participation this year, achieving over 200 percent growth in transactions volume this year, followed by the O2O and e-commerce sectors.
This year, the number of first-time merchant joiners account for about one third of the total global online merchants. During the first ten days of the festival, top-five first-time merchants on average recorded a five-time increase in the number of e-wallet users making payments and a three-time jump in total transaction volumes through Alipay+ compared with the previous month.
“We are excited to see the enthusiasm of consumers during November 11 mega sales this year as online shopping and digital payment have continued to evolve as the key channels for growth over the years,” said Daniel Marogy, Managing Director of foodpanda Philippines.
Introduced by Ant Group in 2020, Alipay+ is a suite of cross-border digital payment, marketing and merchant digitization solutions connecting global brands with mobile-savvy consumers worldwide, with an aim to enable businesses, especially small and medium-sized enterprises, to process a wide range of mobile payment methods and reach more than 1 billion regional and global consumers.
“Alipay+ is dedicated to bringing more exclusive offers and benefits from merchants around the world to hundreds of millions mobile-savvy consumers of our e-wallet partners,” said Jing Yin, General Manager of Acquiring Service and Global Strategic Accounts of Ant Group.
“Ant Group’s technology capabilities and know-how also ensure our merchants and wallet partners are able to process transactions smoothly during peak traffic time, such as the ongoing Alipay+ Double 11 Mega Deals and other promotional events,” he added.
The pandemic has notably accelerated digital adoption. The recent Global Findex data from the World Bank indicated that 8 percent of adults living in developing countries made their first digital payment after Covid-19 started. The research excluded China as the country already has high digital adoption rate and widespread use of mobile payment apps.
Home to the world’s fastest growing e-wallet user base, Southeast Asia is experiencing increasing digitization as 70 percent of the ASEAN population is now online, according to a recent HBSC research. Additionally, the Covid-19 pandemic led to a consumers’ rapid adoption of e-commerce and the demand for online transfer and contactless payments is not fading even as the world gradually recovers from the pandemic.
Over the past six months, Alipay+ has been making steady progress in markets including Southeast Asia, South Korea and Japan, connecting local and regional merchants with various digital payment methods. Last month, Alipay+ introduced three more Asia e-wallets to Singapore and now there are altogether six overseas e-wallets that can accept Alipay+. Alipay+ previously announced new merchant partnership in South Korea and Japan.
During the Singapore Fintech Festival concluded last week, Ant Group also announced that Alipay+’s global merchant coverage has more than doubled to over 2.5 million over the past six months.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221110006198/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
